Background: Intensive therapy of HIV infection with highly active antiretro
viral therapy (HAART) dramatically reduces viral loads and improves immune
status. Abnormalities of lipid levels, body fiat distribution, and insulin
resistance have been commonly reported after starting HAART. Whether the li
pid abnormalities result from changes in metabolism after an improvement in
HIV status or are partly attributable to the effects of protease inhibitor
use is unknown.
Methods: Twenty-one healthy volunteers participated in a 2 week double-blin
d, placebo-controlled study on the effect of the protease inhibitor ritonav
ir on total lipids, apolipoproteins, and post-heparin plasma lipase activit
ies.
Results: Those taking ritonavir (n = 11) had significantly higher levels of
plasma triglyceride, VLDL cholesterol, IDL cholesterol, apolipoprotein B,
and lipoprotein (a) compared with placebo (n = 8). HDL cholesterol was lowe
r with therapy as a result of a reduction in HDL3 cholesterol. Post-heparin
lipoprotein lipase (LpL) activity did not change but hepatic lipase activi
ty decreased 20% (P < 0.01) in those taking ritonavirr-compared with placeb
o. Although all lipoprotein subfractions became triglyceride enriched, most
of the increase in triglyceride was in VLDL and not in IDL particles.
Conclusion: Treatment with ritonavir in the absence of HIV infection or cha
nges in body composition results in hypertriglyceridem ia that is apparentl
y not mediated by impaired LpL activity or the defective removal of remnant
lipoproteins, but could be caused by enhanced formation of VLDL. Long-term
studies of patients with HIV infection receiving HAART will be necessary t
o determine the impact of these drugs and associated dyslipidemia on the ri
sk of coronary artery disease. (C) 2000 Lippincott Williams & Wilkins.